FY20 new start-JW200170: CNP8 delivered topically in a tyrosine

Active Definitive Contract Awarded Last action

Contract number
W81XWH22C0005
Awardee
Awarding agency
Obligated
$2,923,902

Award facts

Contract value 100% obligated
$2,923,902.00 Current and potential, with all options
Completion date 86% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Not Competed · 1 offer Only One Source
Pricing
Fixed Price Level of Effort
Place of performance
Stony Brook, NY 11790, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00006 · CNP8 delivered topically in a tyrosine-derived fiber mat to reduce burn injury progression, speed wound closure, and mitigate scarring. $0
Supplemental Agreement for work within scope P00005 · Research and development of improved wound dressing that is delivered topically. $0
Change Order P00004 · CNP8 delivered topically in a tyrosine-derived fiber mat to reduce burn injury progression, speed wound closure, and mitigate scarring $0
Supplemental Agreement for work within scope P00003 · Research & development for CNP8 for burn injury in support of JPC-6/cccrp at cdmrp. Modification to change subcontractor & update SOW. $0
Supplemental Agreement for work within scope P00002 · Research and development for CNP8 for burn injury in support of JPC-6/cccrp at cdmrp. $0
Other Administrative Action P00001 · Per section 711 of the 2019 ndaa usamraa transferred to DHA 10/1/2022. CNP8 delivered topically in a tyrosine-derived fiber mat to reduce burn injury… $0
Original award FY20 new start-JW200170: CNP8 delivered topically in a tyrosine- derived fiber mat to reduce burn injury progression, speed wound closure, and mitigate scarring $2,923,902

About this award

The Defense Health Agency awarded a $2.92 million fixed-price level-of-effort definitive contract to Neomatrix Therapeutics Inc. on September 8, 2022, with no set-aside used. The prime is described in the source as a self-certified small disadvantaged business. The contract covers development of CNP8, a tyrosine-derived fiber mat delivered topically to reduce burn injury progression, speed wound closure, and mitigate scarring, under FY20 new start JW200170. Work is performed in Stony Brook, NY 11790, with an ultimate completion date of July 31, 2027. The $2.92 million figure is the ceiling value, and the source does not report an obligated amount separately.

Quick answers

Who was awarded contract W81XWH22C0005?

W81XWH22C0005 was awarded to Neomatrix Therapeutics Inc. by Defense Health Agency (Department of Defense) on September 8, 2022.

How much is contract W81XWH22C0005 worth?

The government has obligated $2,923,902 on W81XWH22C0005.

Was contract W81XWH22C0005 competed?

The extent of competition for W81XWH22C0005 was not competed. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award